AcuraStem Inc competitors & alternatives

Aspen NeuroscienceBiotechnologyUnited States

73% match

Biotechnology

Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company headquartered in San Diego, California. The company focuses on developing personalized autologous cell therapies for neurodegenerative diseases.

AsceneuronBiotechnologySwitzerland

72% match

Biotechnology

Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.

NEURONA THERAPEUTICS INCBiotechnologyUnited States

70% matchPrivate

Biotechnology

Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.

Libra TherapeuticsLife SciencesUnited States

69% match

Life Sciences

Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.

ProJenX, Inc.BiotechnologyUnited States

69% matchPrivate

Biotechnology

ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.

Axonis Therapeutics, Inc.BiotechnologyUnited States

69% match

Biotechnology

Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.

Similar biotech company

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

NeuroSense Therapeutics Ltd.NRSN · BiotechHerzliya, Israel

68% matchPublic

Similar biotech company

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Crucible TherapeuticsBiotechnology

68% match

Biotechnology

Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.

Biotechnology

Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.

Biotechnology

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Angiocrine Bioscience, Inc.Life ScienceUnited States

68% matchPrivate

Life Science

Angiocrine Bioscience, Inc. is a private, clinical-stage biotechnology company based in San Diego, California, that develops engineered endothelial cell therapies.